Status:
UNKNOWN
The Therapeutic Evaluation(Both Short-term and Long-term Outcome) of Minimal Invasive Radical Antegrade Modular Pancreatosplenectomy for Left-sided Pancreatic Cancer Patients
Lead Sponsor:
Peking Union Medical College Hospital
Collaborating Sponsors:
Beijing Municipal Health Commission
Conditions:
Pancreatic Cancer
Surgery
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Pancreatic cancer is regarded as "the king of cancer". It is extremely malignant, with a low sensibility to chemotherapy and radiotherapy, and a poor prognosis. Surgical treatment is very important fo...
Detailed Description
Open RAMPS is widely used now to treat pancreatic cancer at the body and tail of pancreas. Meanwhile, laparoscopic surgery is proved to have many advantages in other operations. According to primary r...
Eligibility Criteria
Inclusion
- 18 years old and older;
- Pathology diagnosed as pancreatic adenocarcinoma or suspect cancer mass at the pancreatic body or tail;
- Patients who are eligible and planned to be performed RAMPS procedure;
- Resectable or borderline resectable tumor by preoperative evaluation.
Exclusion
- Patients with evidence of distant metastasis or advanced arterial invasion so that are not able to continue radical surgery;
- ASA≥4；
- Patients who are not willing to be performed open and/or mi-RAMPS;
- Not pancreatic adenocarcinoma by posteroperative pathology.
Key Trial Info
Start Date :
July 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 30 2024
Estimated Enrollment :
125 Patients enrolled
Trial Details
Trial ID
NCT03770559
Start Date
July 1 2020
End Date
December 30 2024
Last Update
May 20 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Beijing, China, 100730